WO2004043363A3 - Protein-stabilized liposomal formulations of pharmaceutical agents - Google Patents

Protein-stabilized liposomal formulations of pharmaceutical agents Download PDF

Info

Publication number
WO2004043363A3
WO2004043363A3 PCT/US2003/035297 US0335297W WO2004043363A3 WO 2004043363 A3 WO2004043363 A3 WO 2004043363A3 US 0335297 W US0335297 W US 0335297W WO 2004043363 A3 WO2004043363 A3 WO 2004043363A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
pharmaceutical agents
liposomal formulations
stabilized liposomal
stabilized liposomes
Prior art date
Application number
PCT/US2003/035297
Other languages
French (fr)
Other versions
WO2004043363A2 (en
WO2004043363A8 (en
Inventor
Chandra U Singh
Original Assignee
Azaya Therapeutics Inc
Chandra U Singh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azaya Therapeutics Inc, Chandra U Singh filed Critical Azaya Therapeutics Inc
Priority to AU2003287526A priority Critical patent/AU2003287526A1/en
Priority to CA2505520A priority patent/CA2505520C/en
Priority to EP03781768A priority patent/EP1585504A4/en
Priority to JP2004551766A priority patent/JP2006508126A/en
Publication of WO2004043363A2 publication Critical patent/WO2004043363A2/en
Publication of WO2004043363A3 publication Critical patent/WO2004043363A3/en
Publication of WO2004043363A8 publication Critical patent/WO2004043363A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)

Abstract

The present invention relates to protein stabilized liposomes. Specifically, the present invention discloses compositions and methods for protein stabilized liposomes, the creation of protein stabilized liposomes, and the administration of protein stabilized liposomes.
PCT/US2003/035297 2002-11-06 2003-11-06 Protein-stabilized liposomal formulations of pharmaceutical agents WO2004043363A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003287526A AU2003287526A1 (en) 2002-11-06 2003-11-06 Protein-stabilized liposomal formulations of pharmaceutical agents
CA2505520A CA2505520C (en) 2002-11-06 2003-11-06 Protein-stabilized liposomal formulations of pharmaceutical agents
EP03781768A EP1585504A4 (en) 2002-11-06 2003-11-06 Protein-stabilized liposomal formulations of pharmaceutical agents
JP2004551766A JP2006508126A (en) 2002-11-06 2003-11-06 Protein-stabilized liposome formulation of pharmaceutical formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42423002P 2002-11-06 2002-11-06
US60/424,230 2002-11-06

Publications (3)

Publication Number Publication Date
WO2004043363A2 WO2004043363A2 (en) 2004-05-27
WO2004043363A3 true WO2004043363A3 (en) 2004-08-12
WO2004043363A8 WO2004043363A8 (en) 2005-07-28

Family

ID=32312773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/035297 WO2004043363A2 (en) 2002-11-06 2003-11-06 Protein-stabilized liposomal formulations of pharmaceutical agents

Country Status (6)

Country Link
US (2) US7179484B2 (en)
EP (1) EP1585504A4 (en)
JP (1) JP2006508126A (en)
AU (1) AU2003287526A1 (en)
CA (1) CA2505520C (en)
WO (1) WO2004043363A2 (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004018478A2 (en) 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
WO2004096140A2 (en) * 2003-04-25 2004-11-11 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
EP1697035B1 (en) * 2003-12-22 2017-11-15 Warren H. Finlay Powder formation by atmospheric spray-freeze drying
JP2008500364A (en) * 2004-05-25 2008-01-10 キメラコア， インコーポレイテッド Self-assembling nanoparticle drug delivery system
US7906140B2 (en) * 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
GB0416120D0 (en) * 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's
US20060110441A1 (en) * 2004-10-28 2006-05-25 Harry Wong Lyophilized liposome formulations and method
EP1906948A4 (en) * 2005-07-18 2010-03-17 Bipar Sciences Inc Treatment of cancer
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
KR101420445B1 (en) * 2005-08-31 2014-07-16 아브락시스 바이오사이언스, 엘엘씨 Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
JP2009512682A (en) * 2005-10-21 2009-03-26 パナセア バイオテック リミテッド Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
AU2007348315A1 (en) * 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating B- cell malignancies
US20090311329A1 (en) * 2006-04-20 2009-12-17 Technion Research And Development Foundation Ltd Casein micelles for nanoencapsulation of hydrophobic compounds
EP2018875A1 (en) * 2006-05-15 2009-01-28 Ebara Corporation Poorly-water-soluble pharmaceutical agent
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
EP2038654A4 (en) * 2006-06-12 2010-08-11 Bipar Sciences Inc Method of treating diseases with parp inhibitors
US8728527B2 (en) * 2006-07-24 2014-05-20 Luminus Biosciences, Inc. Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening
US8143447B2 (en) * 2006-09-05 2012-03-27 Bipar Sciences, Inc. Treatment of cancer
JP2010502731A (en) * 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
CN101209243B (en) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 Liposome medicament and preparation thereof
CA2683063A1 (en) * 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
TW200846031A (en) * 2007-05-25 2008-12-01 Shu-Yi Lin Drug delivery system and the preparing method thereof
WO2009006311A2 (en) * 2007-06-29 2009-01-08 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
US20120003294A1 (en) * 2007-08-17 2012-01-05 Celator Pharmaceuticals, Inc. Fixed ratio camptothecens/platinum agents
KR100996975B1 (en) 2007-08-24 2010-11-29 한국화학연구원 Liposome coated with protein to prolong circulation time in bloodstream and preparation method thereof
US20090149417A1 (en) * 2007-10-19 2009-06-11 Valeria Ossovskaya Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors
MX2010005222A (en) * 2007-11-12 2010-09-28 Bipar Sciences Inc Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents.
EP2217244A4 (en) * 2007-11-12 2011-08-31 Bipar Sciences Inc Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
KR20100102637A (en) * 2007-12-07 2010-09-24 바이파 사이언스 인코포레이티드 Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
CN101485629B (en) * 2008-01-16 2013-01-23 沈阳药科大学 Drug delivery system and preparation method thereof
WO2009101613A1 (en) * 2008-02-11 2009-08-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
US8865222B2 (en) * 2008-02-11 2014-10-21 Technion Research And Development Foundation Ltd. Beta-casein assemblies for enrichment of food and beverages and methods of preparation thereof
EP2252269A1 (en) * 2008-02-11 2010-11-24 Technion Research and Development Foundation, Ltd. Casein particles encapsulating therapeutically active agents and uses thereof
US8871276B2 (en) 2008-02-11 2014-10-28 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
EP2599476A1 (en) * 2008-04-04 2013-06-05 Lipella Pharmaceuticals, Inc. Treatment of bladder dysfunction using liposomal botulinum toxin
KR100890317B1 (en) * 2008-05-08 2009-03-26 고려대학교 산학협력단 Compositions of platinium and thereof formulations
CA2725535C (en) * 2008-05-23 2016-01-05 The University Of British Columbia Modified drugs for use in liposomal nanoparticles
US20110092493A1 (en) * 2008-09-24 2011-04-21 Clark Levi Dose-controlled transdermal promethazine compositions and methods of use
US9445975B2 (en) 2008-10-03 2016-09-20 Access Business Group International, Llc Composition and method for preparing stable unilamellar liposomal suspension
US20100120727A1 (en) * 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
FR2945946B1 (en) * 2009-05-29 2011-08-26 Univ Victor Segalen Bordeaux 2 MULTI-COMPARTMENT FORMULATIONS BASED ON FUNCTIONAL AMPHIPHILIC MOLECULES OR MACROMOLECULES
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011068491A1 (en) 2009-12-01 2011-06-09 The Board Of Trustees Of The Leland Stanford Junior University Tumor vaccination in combination with hematopoietic cell transplantation for cancer therapy
DK2525782T3 (en) * 2010-01-18 2019-06-11 Concept Medical Res Private Limited Formulations of nanotubes and methods of making them
WO2011119262A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
WO2011160110A1 (en) 2010-06-19 2011-12-22 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
KR101130754B1 (en) * 2010-06-25 2012-03-28 제일약품주식회사 Pharmaceutical compositions having improved solubility of poorly soluble tricyclic derivative compounds
KR101742852B1 (en) 2010-11-22 2017-06-15 피닉스 바이오테크놀러지 인코포레이티드. Method of treating neurological conditions with extract of nerium species or thevetia species
US8546521B2 (en) 2011-01-28 2013-10-01 Cerulean Pharma Inc. Method for fabricating nanoparticles
US20120232005A1 (en) * 2011-02-07 2012-09-13 Cerenis Therapeutics Holding S.A. Lipoprotein complexes and manufacturing and uses thereof
JP6061343B2 (en) * 2011-04-04 2017-01-18 学校法人早稲田大学 Production method of endoplasmic reticulum
JP2014527072A (en) 2011-09-09 2014-10-09 バイオメド リアルティー， エル．ピー． Methods and compositions for controlling the assembly of viral proteins
CN104114156A (en) * 2011-10-21 2014-10-22 切拉托尔制药公司 Lyophilized liposomes
IN2014DN09950A (en) 2012-05-30 2015-08-14 Klox Technologies Inc
KR101360143B1 (en) 2012-09-26 2014-02-11 씨에스아이알 Composition for preventing or treating dementia comprising extracts of monsonia sp.
KR101373755B1 (en) 2012-09-26 2014-03-14 씨에스아이알 Composition containing arylnaphthalene lignan derivative for preventing and/or treating dementia
CA2903255C (en) * 2013-03-13 2018-08-28 Mallinckrodt Llc Modified docetaxel liposome formulations
WO2014143806A1 (en) * 2013-03-15 2014-09-18 The Penn State Research Foundation Acid stable liposomal compositions
RS61273B1 (en) 2014-04-30 2021-01-29 Fujifilm Corp Liposome composition and production method therefor
EP3138558B1 (en) * 2014-04-30 2023-06-07 FUJIFILM Corporation Liposome composition and production method therefor
US20160346221A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
EP3334416A1 (en) 2015-08-11 2018-06-20 Eyesiu Medicines B.V. Pegylated lipid nanoparticle with bioactive lipophilic compound
KR102116048B1 (en) * 2015-10-07 2020-06-05 엔스이코 세이토 가부시키가이샤 Liposomes containing taxane compounds
CA3027368A1 (en) 2016-06-13 2017-12-21 Ascendia Pharmaceuticals, Llc Parenteral sustained-release delivery of carvedilol disperse systems
ES2874187T3 (en) 2016-09-14 2021-11-04 Phoenix Biotechnology Inc Method and compositions for the treatment of a viral infection
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
EP3655418A4 (en) 2017-06-22 2021-05-19 Triact Therapeutics, Inc. Methods of treating glioblastoma
CN110996911B (en) * 2017-06-26 2023-01-17 福多兹制药公司 Aprepitant nano-microcapsule preparation as well as method and application thereof
WO2019032437A1 (en) * 2017-08-09 2019-02-14 Cytori Therapeutics, Inc. Liposomal taxanes for treatment of sclc
EP3681508A4 (en) 2017-09-14 2021-05-19 Phoenix Biotechnology, Inc. Method and composition for treating viral infection
WO2019067991A1 (en) 2017-09-29 2019-04-04 Triact Therapeutics, Inc. Iniparib formulations and uses thereof
KR102464428B1 (en) 2020-03-31 2022-11-04 피닉스 바이오테크놀러지 인코포레이티드. Methods and compositions for treatment of coronavirus infection
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
WO2023212621A1 (en) * 2022-04-26 2023-11-02 University Of Virginia Patentfoundation Development of nano-encapsulated fatty-acyl conjugated colchicine
EP4299053A1 (en) * 2022-06-28 2024-01-03 Vysoká skola chemicko-technologická v Praze Method for preparing an aqueous nanosuspension containing nanocrystals of pharmaceutically active ingredient and a combination of stabilizers, aqueous nanosuspension and use thereof
CN115399481B (en) * 2022-07-21 2023-08-22 江苏集萃先进高分子材料研究所有限公司 Functional edible film loaded with probiotics and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182330A (en) * 1977-07-25 1980-01-08 Alza Corporation Means for administering amphipathic medicament
IL64397A0 (en) * 1981-01-07 1982-02-28 Weder Hans G Process for the preparation of liposomal medicaments
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4515736A (en) * 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
JPS607932A (en) * 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd Preparation of liposome
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
JPS6137735A (en) * 1984-07-31 1986-02-22 Terumo Corp Hemoglobin-containing liposome and its preparation
US5230899A (en) * 1985-08-07 1993-07-27 Smithkline Beecham Corporation Methods and compositions for making liposomes
EP0225130B1 (en) * 1985-11-22 1991-10-30 Takeda Chemical Industries, Ltd. Liposome composition
US5723147A (en) * 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5178875A (en) * 1991-01-14 1993-01-12 The Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
US4873035A (en) * 1987-11-25 1989-10-10 Abbott Laboratories Preparation of sized populations of liposomes
US5807572A (en) * 1988-02-18 1998-09-15 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
WO1990003795A1 (en) * 1988-10-05 1990-04-19 Vestar, Inc. Method of making liposomes with improved stability during drying
US5185154A (en) * 1989-02-02 1993-02-09 Liposome Technology, Inc. Method for instant preparation of a drug containing large unilamellar vesicles
US5277914A (en) * 1989-03-31 1994-01-11 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
CA2046997C (en) * 1990-07-16 2000-12-12 Hiroshi Kikuchi Liposomal products
DE4111982C2 (en) * 1991-04-12 1998-12-24 Merz & Co Gmbh & Co Stable small particulate liposome preparations, their preparation and use
WO1992018104A1 (en) * 1991-04-19 1992-10-29 Vestar, Inc. Pharmaceutical formulation and process
US5260065A (en) * 1991-09-17 1993-11-09 Micro Vesicular Systems, Inc. Blended lipid vesicles
US6372249B1 (en) * 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
JPH06247842A (en) * 1993-02-23 1994-09-06 Green Cross Corp:The Production of liposome composition
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
DK0678017T3 (en) * 1993-11-05 1998-10-19 Amgen Inc Liposome preparation and material encapsulation method
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5766627A (en) * 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
CA2176712C (en) * 1993-11-16 2000-05-23 Mantripragada Sankaram Synthetic membrane vesicles with controlled release of encapsulated biologically active substances
US5446074A (en) * 1993-12-17 1995-08-29 International Business Machines Corporation Photosensitive polyimide precursors
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US5589189A (en) * 1994-09-14 1996-12-31 Nexstar Pharmaceuticals, Inc. Liposome dispersion
EP0783295A1 (en) * 1994-09-23 1997-07-16 The Liposome Company, Inc. Method of producing a lyophilized liposome product
US5702722A (en) * 1994-09-30 1997-12-30 Bracco Research S.A. Liposomes with enhanced entrapment capacity, method and use
US6007838A (en) * 1995-06-07 1999-12-28 The United States Of America As Represented By The Secretary Of The Army Process for making liposome preparation
US5753262A (en) * 1995-06-07 1998-05-19 Aronex Pharmaceuticals, Inc. Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof
JP2000502087A (en) * 1995-12-15 2000-02-22 ナショナル リサーチ カウンシル オブ カナダ Archeosomes, arceosomes containing coenzyme Q, and other types of liposomes containing coenzyme Q, as adjuvants and delivery vehicles
US6447800B2 (en) * 1996-01-18 2002-09-10 The University Of British Columbia Method of loading preformed liposomes using ethanol
AU727447B2 (en) * 1996-07-03 2000-12-14 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
US6770291B2 (en) * 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
CA2263705C (en) * 1996-08-19 2007-12-04 Nancy Smyth-Templeton Novel sandwich liposome complexes comprising a biologically active agent
DE19642976A1 (en) * 1996-10-18 1998-04-23 Pfeiffer Erich Gmbh & Co Kg Discharge device for media
WO1998024415A1 (en) * 1996-12-02 1998-06-11 The Regents Of The University Of California A bilayer structure which encapsulates multiple containment units and uses thereof
US6565889B2 (en) * 1996-12-02 2003-05-20 The Regents Of The University Of California Bilayer structure which encapsulates multiple containment units and uses thereof
WO1998055104A1 (en) * 1997-06-06 1998-12-10 Shionogi & Co., Ltd. Improvement in medicament administration system
US6306433B1 (en) * 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6106858A (en) * 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
US20020039596A1 (en) * 1997-11-14 2002-04-04 Hartoun Hartounian Production of multivesicular liposomes
US20030044454A1 (en) * 1998-06-30 2003-03-06 Masaru Fukui Compositions containing liposomes and/or emulsions and process for the preparation thereof
ATE428371T1 (en) * 1998-07-17 2009-05-15 Pacira Pharmaceuticals Inc BIODEGRADABLE ARRANGEMENTS FOR THE CONTROLLED RELEASE OF ENCLOSED SUBSTANCES
AU773515B2 (en) * 1999-02-08 2004-05-27 Alza Corporation Method for controlling liposome size
CH693625A5 (en) * 1999-02-18 2003-11-28 Inpharma Sa Pharmaceutical compositions containing compounds of promoter activity of absorption of active ingredients.
US6328988B1 (en) * 1999-04-23 2001-12-11 Rutgers, The State University Of New Jersey Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules
DE19954843C2 (en) * 1999-11-09 2003-11-20 Novosom Ag Process for encapsulating proteins or peptides in liposomes, liposomes produced by the process and their use
US20020001613A1 (en) * 2000-02-08 2002-01-03 Susan Niemiec Method of manufacturing liposomes
US20020119188A1 (en) * 2000-02-08 2002-08-29 Susan Niemiec Method of manufacturing liposomes
ES2253398T3 (en) * 2000-06-30 2006-06-01 Inex Pharmaceuticals Corp. IMPROVED LIPOSOMAL CAMPTOTECINS AND THEIR USES.
ATE396707T1 (en) * 2000-12-01 2008-06-15 Biomira Inc PRODUCTION OF LARGE LIPOSOMES BY INFUSION IN PEG
US6576625B2 (en) * 2001-03-16 2003-06-10 Panacea Biotic Limited Targeted vesicular constructs for cytoprotection and treatment of H. pylori infections
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] PAJEAN M. ET AL: "Stabilization of liposomes with collagen", XP002979043, retrieved from STN Database accession no. 1992:91224 *
DATABASE CAPLUS [online] SULKOWSKA A.: "Effect of serum albumin presence on the binding constant of metronidazole to the phopholipid membranes. Fluorescence study", XP002979044, retrieved from STN Database accession no. 1999:376306 *
INT'L J. OF PHARMACEUTICS, vol. 77, no. 1, 1991, pages 31 - 40 *
J. OF MOLECULAR STRUCTURE, vol. 480-481, 1999, pages 581 - 584 *

Also Published As

Publication number Publication date
WO2004043363A2 (en) 2004-05-27
US7179484B2 (en) 2007-02-20
US20070166368A1 (en) 2007-07-19
US20040247660A1 (en) 2004-12-09
WO2004043363A8 (en) 2005-07-28
EP1585504A2 (en) 2005-10-19
JP2006508126A (en) 2006-03-09
EP1585504A4 (en) 2009-07-15
AU2003287526A1 (en) 2004-06-03
AU2003287526A8 (en) 2004-06-03
CA2505520A1 (en) 2004-05-27
CA2505520C (en) 2012-07-17

Similar Documents

Publication Publication Date Title
WO2004043363A8 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
WO2004026231A3 (en) Formulation for lipophilic agents
WO2000055126A3 (en) N-cyanomethylamides as protease inhibitors
WO2003002136A3 (en) Stable formulation of modified glp-1
WO2002080965A3 (en) Vaccine composition
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
AU2003296897A1 (en) Pharmaceutical formulations of camptothecine derivatives
AU2003229555A1 (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
WO2005065317A3 (en) Effervescent oral fentanyl dosage form
WO2000055124A3 (en) Novel compounds and compositions as protease inhibitors
WO2003045306A3 (en) Phenoxy amine compounds and compositions for delivering active agents
WO2004047792A3 (en) Liposomal glucocorticoids
WO2005027822A3 (en) Stabilized formulations of phosphatidylserine
WO2001005355A3 (en) Formulations for il-11
MXPA03007857A (en) Compounds and compositions for delivering active agents.
WO2002015959A3 (en) Compounds and compositions for delivering active agents
WO2003045330A3 (en) Materials and methods for making improved micelle compositions
WO2001068645A3 (en) N-cyanomethylcarboxamides and their use as protease inhibitors
AU777185C (en) Pharmaceutical form of administration for peptides, methods for its production and use
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
MXPA03010054A (en) Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents.
WO2003068157A3 (en) Kinase inhibitors and methods of use thereof
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
AU2003294762A1 (en) Film-type preparations for transmucosal administration of nicotine and method for the production thereof
WO2003039437A3 (en) Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2505520

Country of ref document: CA

Ref document number: 2004551766

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003781768

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 22/2004 UNDER (71) REPLACE "(FOR US ONLY)" BY "(FOR ALL DESIGNATED STATES EXCEPT US)"

WWP Wipo information: published in national office

Ref document number: 2003781768

Country of ref document: EP